Global Epilepsy Market: Industry Analysis & Outlook 2017-2021 - Epilepsy Market Driven by High Prevalence of Central Nervous Systems Diseases - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Epilepsy Market: Industry Analysis & Outlook (2017-2021)" report to their offering.

Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones.

Epilepsy is divided into four main types; idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy and symptomatic partial epilepsy. The cause of epilepsy can be genetic, a result of other disorders such as tumor or brain injury and due to certain seizure triggers.

Epilepsy is treated via antiepileptic drugs, surgery in certain cases and several complementary therapies such as ketogenic diets or neural stimulation. Based upon the drug type, epilepsy market can be divided into three main categories; first generation drugs, second generation drugs and third generation drugs.

The global epilepsy market is driven by factors such as development of novel drugs, launch of new drugs in developing regions and prevalence of neural disorders such as meningitis and tumors. This growth is then further spearheaded by increasing healthcare expenses and rising disposable incomes. However, the market growth is hindered by tedious drug approval process, generic erosion and high cost of treatment. Trends such as companies focusing on developing effective therapies for refractory epilepsy and physicians demanding higher efficacy drugs are listed in this report.

The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Novartis AG., Pfizer Inc., GlaxoSmithKline Plc. and UCB are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global epilepsy drugs market along with the study of the regional markets.

Market Dynamics

Growth Drivers

  • Increasing Healthcare Expenditure
  • Rising Disposable Income
  • Development of Novel Drugs
  • Prevalence of Neurological Disease and Brain Infections
  • Launch of New Drugs in Underpenetrated Developing Countries

Trends

  • Physicians Desire Higher Efficacy Drugs
  • Focus on Development of Therapeutics for Refractory Epilepsy

Challenges

  • Hasty Drug Approval Process
  • Generic Erosion
  • High Cost of Antiepileptic Drugs

Companies Mentioned

  • GlaxoSmithKline Plc.
  • Novartis AG
  • Pfizer Inc.
  • UCB

For more information about this report visit http://www.researchandmarkets.com/research/w22p4q/global_epilepsy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Central Nervous System Drugs